Press releases

Press releases

Inotrem announces positive results from the Phase IIa study of its lead compound, nangibotide (LR12), in the treatment of septic shock.

The study demonstrated the safety and tolerability of its lead compound in patients suffering from septic shock Paris, October 1st. 2018. Inotrem S.A., a biotechnology focused on the modulation of the TREM pathway for the management of inflammatory syndromes, announced positive results for its Phase IIa study that demonstrated the

Read More »

Martin Koch joins Inotrem as Chief Operating Officer

Paris, January 18th . 2018. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes such as septic shock, has appointed Martin Koch as Chief Operating Officer (COO). Martin Koch comes to Inotrem with more than 25 years of experience in the healthcare industry. Prior to joining

Read More »

Inotrem announces new preclinical data supporting its lead compound’s (LR12) positive role on vascular dysfunction during septic shock

Paris, September 13 th. 2017. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes, such as septic shock, announced today that preclinical results show a direct and strong protective effect of its lead product candidate LR12 on vascular function during experimental septic shock. The firm was

Read More »

Inotrem successfully completes its first phase I clinical trial with Motrem, a TREM-1 pathway modulator for the treatment of septic shock.

Paris, France, September 13, 2016 – Inotrem SA, a biotechnology company specialized in the control of acute inflammatory syndromes, such as septic shock, announced today the successful completion of the first clinical trial of Motrem in healthy volunteers. The principal objective of this first in-man phase I clinical trial, conducted

Read More »